Sort
48,018 grants matching “immunotherapy”
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,005,132Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Unleashing T-cell anti-tumor response through repair of altered RNA splicing and antigen mimicry recognition
$1,005,000Luisa Escobar Hoyos · Yale University · DP2 · FY2025 · CA
Augmem: A Novel Digital Cognitive Assessment for the Early Detection of Alzheimer's Disease
$1,004,853Adele Gilpin · Augnition Labs Llc · R44 · FY2022 · AG
INSIDE-OUT IMMUNOTHERAPY: PREVENTING METASTATIC BREAST CANCER RECURRENCE VIA NANOPARTICLE-DIRECTED MODULATION OF THE TUMOR MICROENVIRONMENT
$1,004,565Vanderbilt University · · FY2016 · Department of the Army
05 Tissue Biospecimen and Pathology Resource
$1,004,287Ignacio I. Wistuba · University Of Tx Md Anderson Can Ctr · P30 · FY2024 · CA
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
$1,004,278Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2019 · CA
The role of clonal hematopoiesis in the development and therapy of myeloid malignancies
$1,004,250Benjamin Levine Ebert · Dana-Farber Cancer Inst · R35 · FY2020 · CA
The role of clonal hematopoiesis in the development and therapy of myeloid malignancies
$1,004,250Benjamin Levine Ebert · Dana-Farber Cancer Inst · R35 · FY2021 · CA
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
$1,004,241Song Yao · Roswell Park Cancer Institute Corp · UG3 · FY2022 · CA
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy
$1,004,186Scott Budd Winram · Cynvec, Llc · R44 · FY2017 · CA
Mesothelin-targeted immunotoxins in Pancreatic Cancer
$1,004,043Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Determining the contribution of microbial-derived metabolites to protective immunity in obesity-driven cancer risk.
$1,003,836Liza Makowski Hayes · University Of Tennessee Health Sci Ctr · U01 · FY2024 · CA
Determinants of response to cancer immunotherapy
$1,002,984Lawrence Fong · Fred Hutchinson Cancer Center · R35 · FY2024 · CA
Pig-to-Monkey Islet Xenotransplantation
$1,002,980Bernhard Josef Hering · University Of Minnesota · U01 · FY2019 · AI
Autoimmunity: Mechanisms of Unresponsiveness
$1,002,938Charles Garrison Fathman · Stanford University · P01 · FY2007 · AI
Autoimmunity: Mechanisms of Unresponsiveness
$1,002,489Stanford University · P01 · FY2005 · AI
Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer
$1,002,483Valerie Humblet · Collagen Medical, Llc · R44 · FY2017 · CA
Time-lapse Flow Cytometry for Kinetic Profiling of T-Cell Function
$1,002,340Sheldon J.j. Kwok · Lase Innovation Inc. · R44 · FY2023 · CA
Photodynamic Priming of Cancer and Image-guidance for Optimal Immune Response
$1,002,287Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2024 · CA
A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis
$1,001,952Gary Fanger · Rise Therapeutics, Llc · R44 · FY2023 · DK
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
$1,001,898Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2019 · CA
Clinical Support
$1,001,704James J Vredenburgh · Duke University · P01 · FY2016 · CA
EpCAM (CD326) Function in Epithelial Cell Biology and Immunophysiology
$1,001,575Mark Udey · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
ANTIGEN-SPECIFIC VACCINES FOR BREAST CANCER
$1,001,273Johns Hopkins University · U19 · FY2001 · CA
Clinical production of viral vectors for cancer gene therapy
$1,001,150Steven Feldman · Division Of Basic Sciences - Nci · ZIC · FY2015 · CA